Crossmark

Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching comparative study

Crossref DOI link: https://doi.org/10.1007/s12072-025-10884-6

Published Online: 2025-08-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, ChunXue

Yang, Hongcai

Zhang, Weihao

Cao, Fei

Li, Xinge

Sun, Peng

Zhang, Dianliang

Shao, Wenbo

Sun, Pengfei

Chang, Xu
Funding

Funding for this research was provided by:

Natural Science Foundation of Shandong Province (ZR2023QH127)
License Information

Text and Data Mining valid from 2025-08-04

Version of Record valid from 2025-08-04
More Information

Article History

Received: 27 April 2025

Accepted: 18 July 2025

First Online: 4 August 2025

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: The current study had approval from the Ethics Committees of Shandong Cancer Hospital and Institute (SDTHEC 2023004006).

: Written informed consent was waived because of the retrospective design of this study.

: All authors agreed to the submission and publication of this study to this journal.

Document is current

Any future updates will be listed below